glp-1 drug novo nordisk promotes new receptor agonist to fight diabetes, obesity < Pharma < Article Novo Nordisk cuts prices as

2013;369:145-154) found that intensive lifestyle intervention focused on weight loss did not reduce cardiovascular events in a large cohort of adults with overweight/obesity and type 2 diabetes

A study using the Control of Eating Questionnaire (CoEQ) has reported that semaglutide treatment reduced hunger, appetite, and interest in high-palatability foods while also diminishing the pleasure of eating [17]

Model-based meta-analysis: an important tool for making quantitative decisions during drug development

Additionally, if the FDA approves more uses for these medicines, insurance companies will be less likely to object to prescribing GLP-1s for uses beyond diabetes and weight loss

In extensive studies involving large groups of individuals, the utilization of incretinbased therapy did not demonstrate a higher likelihood of hospitalization due to severe pancreatitis [163] or pancreatic cancer [164]

Adherence to treatment in chronic diseases is an old but still relevant problem involving factors related to the treatment regimen, the patient and/or the health care providers